Cerliponase alfa clinical trials
Also written Brineura and BMN 190.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses cerliponase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 27 Apr 2017 · BRINEURA · BLA 761052 (FDA, Drugs@FDA)
- European Union
- 30 May 2017 · Brineura · EMEA/H/C/004065 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
BioMarin Pharmaceutical (3) · David L Rogers, MD (1)
Studies
Open first, then newest update. How each study uses cerliponase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2Active, not recruitingPhase 1/2David L Rogers, MDNCT05152914Written as Cerliponase Alfa
- A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 DiseaseCompletedPhase 2BioMarin PharmaceuticalNCT02678689Written as BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)
- An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 DiseaseCompletedPhase 1/2BioMarin PharmaceuticalNCT02485899Written as BMN 190
- A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) DiseaseCompletedPhase 1/2BioMarin PharmaceuticalNCT01907087Written as BMN 190
Codes
What other systems call cerliponase alfa · ClinicalTrials.gg INT000738
- MeSH (NLM) C000621431cerliponase alfaOne source ClinicalTrials.gov
- UNII (FDA) X8R2D92QP1CERLIPONASE ALFAConfirmed FDA, Wikidata
- RxNorm 1922436Confirmed FDA, Wikidata
- Wikidata Q33626059cerliponase alfaConfirmed FDA, Wikidata
- NCI Thesaurus C169840Cerliponase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621431 | cerliponase alfa | One source ClinicalTrials.gov |
| UNII (FDA) | X8R2D92QP1 | CERLIPONASE ALFA | Confirmed FDA, Wikidata |
| RxNorm | 1922436 | — | Confirmed FDA, Wikidata |
| Wikidata | Q33626059 | cerliponase alfa | Confirmed FDA, Wikidata |
| NCI Thesaurus | C169840 | Cerliponase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.